Roche

Rituximab Hits Endpoints for New Indication

Tuesday, February 5, 2008

Roche issued positive results from a phase III trial of MabThera (Rituxan, rituximab) as a first-line therapy for rheumatoid arthritis. This international, randomized, placebo controlled, double blind, parallel group study was dubbed SERENE (Study Evaluating Rituximab’s Efficacy in methotrexate iNadequate rEsponders).

[Read More]